Table 4.
Inclusion criteria and study quality of included cardiovascular outcomes trials
| Trial | Cohort | Quality of study* |
|---|---|---|
| ABCD46 | Patients with long or multivessel disease undergoing PCI | ++± |
| ACCEL-AMI29 | Patients with ACS undergoing PCI | +++ |
| ACCEL-LOADING-ACS30 | Patients with non-ST-elevation MI undergoing PCI | ±±± |
| ACCEL-RESISTANCE33 | Patients with high on-treatment platelet reactivity undergoing PCI | ++± |
| Ahn et al47 | Patient with ACS undergoing PCI | ±±+ |
| Chen et al48 | Patients with ACS undergoing PCI | ±++ |
| CIDES49 | Patients with diabetes undergoing PCI | ±±± |
| CILON-T34 | Patients with angina undergoing PCI | ++± |
| CLEAR50 | Patients with stable angina undergoing PCI | ±±± |
| CREST51 | Patients with ACS/known stenosis undergoing PCI | +++ |
| DECLARE-DIABETES52 | Patients with ACS and diabetes undergoing PCI | +±± |
| DECLARE-LONG54 | Patients with ACS and stenosis of long (>25 mm) lesions undergoing PCI | +±± |
| DECLARE-LONG II55 | Patients with ACS/known stenosis of long (>25 mm) lesions undergoing PCI | +++ |
| Gao et al35 | Obese patients undergoing PCI | ±±± |
| Guan et al36 | Patients with ACS and high on-treatment platelet reactivity undergoing PCI | ±±± |
| Han et al56 | Patients with ACS undergoing PCI | ++± |
| Han et al57 | Patients with ACS undergoing PCI | ±±± |
| HOST-ASSURE37 | All-comer patients undergoing PCI | ±±+ |
| Hu et al58 | Patients with ACS undergoing PCI | ±±± |
| Jin et al39 | Patients undergoing PCI | ±++ |
| Kim et al59 | Patients with ACS/known stenosis undergoing PCI | ±±± |
| Kim et al41 | Patients with ST-elevation MI undergoing PCI | ±±± |
| Kum et al42 | Patients with ACS/known stenosis undergoing PCI | ±±± |
| Lee et al60 | Patients undergoing elective PCI | +±± |
| LONG-DES-II61 | Patients with stenosis of long lesions undergoing PCI | ++± |
| Lu et al70 | Patients undergoing PCI | ±±+ |
| Lu et al64 | Patients with ADP-induced platelet inhibition rates <30% undergoing PCI | +±± |
| Min et al10 | Patients with ACS/known stenosis undergoing elective PCI | ±+± |
| OPTIMUS-26 | Patients with diabetes undergone PCI | +++ |
| Shen et al65 | Patients with ACS undergoing PCI | ±±± |
| Suh et al66 | Patients with diabetes and chronic total occlusion undergoing PCI | ±±± |
| Wang et al67 | Patients with small vessel stenosis undergoing PCI | ±±± |
| Wang et al68 | Patients with non-ST-elevation MI undergoing PCI | ±±± |
| Zang et al69 | Patients with ACS undergoing PCI | ±±± |
*Represents risk of bias based on: sequence generation of allocation; allocation concealment and blinding. ‘+’ represents low bias risk, ‘−’ high bias risk and ‘±’ unclear bias risk.
ABCD, Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients with Long or Multivessel Coronary Artery Disease underwent Biolimus-Eluting Stent Implantation; ACS, acute coronary syndrome; AMI, acute myocardial infarction; BES, biolimus-eluting stent; BMS, bare metal stent; CIDES, comparison of cilostazol versus clopidogrel after drug-eluting stenting in diabetic patients; CILON-T, Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; CLEAR, The Cilostazol Administration Before Percutaneous Coronary Intervention for Reduction of Periprocedural Myonecrosis Trial; CREST, Coronary Stent Restenosis in Patients Treated with Cilostazol; DECLARE-LONG II: Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions; DECLARE-DIABETES, A Randomised Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients; DECLARE-LONG, Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions; DES, drug-eluting stent; DM, diabetes mellitus; EES, everolimus-eluting stent; EES-PtCr, everolimus-eluting platinum-chromium alloy stent; LONG-DES, Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease; OPTIMUS-2, Impact of Cilostazol on Platelet Function Profiles in Patients with Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy; PES, Paclitaxel-eluting stent; SES, Sirolimus-eluting stent; ZES, Zotarolimus-eluting stent; ZES-R, Zotarolimus-eluting Resolute stent.